Media headlines about BeiGene (NASDAQ:BGNE) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. BeiGene earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave news stories about the company an impact score of 49.1422050671024 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Maxim Group Increases BeiGene (BGNE) Price Target to $225.00 (americanbankingnews.com)
- BRIEF-Beigene Initiates Phase 3 Trial Of Pamiparib As Maintenance Therapy In Chinese Patients With Ovarian Cancer (reuters.com)
- BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian Cancer (finance.yahoo.com)
- BeiGene to Present at the 2018 UBS Global Healthcare Conference (finance.yahoo.com)
- BeiGene (BGNE) Rating Lowered to Sell at Zacks Investment Research (americanbankingnews.com)
Shares of BeiGene traded up $5.44, hitting $194.55, on Friday, Marketbeat reports. The company’s stock had a trading volume of 234,485 shares, compared to its average volume of 376,283. The company has a debt-to-equity ratio of 0.12, a quick ratio of 11.12 and a current ratio of 11.18. BeiGene has a fifty-two week low of $36.51 and a fifty-two week high of $195.00. The company has a market capitalization of $9.81 billion, a PE ratio of -87.24 and a beta of 0.29.
BeiGene (NASDAQ:BGNE) last released its quarterly earnings results on Wednesday, May 9th. The company reported ($2.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.62) by ($0.41). The company had revenue of $32.54 million for the quarter, compared to analyst estimates of $16.88 million. During the same quarter in the previous year, the business earned ($1.27) EPS. analysts forecast that BeiGene will post -8.23 EPS for the current year.
Several research firms have commented on BGNE. Maxim Group set a $200.00 price objective on shares of BeiGene and gave the company a “buy” rating in a report on Thursday, May 10th. Zacks Investment Research downgraded shares of BeiGene from a “hold” rating to a “sell” rating in a report on Monday. BidaskClub upgraded shares of BeiGene from a “hold” rating to a “buy” rating in a report on Wednesday, January 31st. Finally, Robert W. Baird reiterated a “hold” rating and issued a $138.00 price objective on shares of BeiGene in a report on Thursday, March 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. BeiGene currently has an average rating of “Buy” and an average price target of $173.00.
In other BeiGene news, CFO Howard Liang sold 40,000 shares of the stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $160.27, for a total transaction of $6,410,800.00. Following the sale, the chief financial officer now directly owns 15,872 shares in the company, valued at $2,543,805.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO John Oyler sold 99,000 shares of the stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $145.63, for a total transaction of $14,417,370.00. Following the sale, the chief executive officer now owns 93,883 shares in the company, valued at $13,672,181.29. The disclosure for this sale can be found here. Insiders sold 194,210 shares of company stock worth $29,041,676 over the last 90 days. 19.90% of the stock is currently owned by corporate insiders.
BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.